Chronic lymphocytic leukemia diagnostic study of choice
|
Chronic lymphocytic leukemia Microchapters |
|
Differentiating Chronic lymphocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic lymphocytic leukemia diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Chronic lymphocytic leukemia diagnostic study of choice |
|
FDA on Chronic lymphocytic leukemia diagnostic study of choice |
|
CDC on Chronic lymphocytic leukemia diagnostic study of choice |
|
Chronic lymphocytic leukemia diagnostic study of choice in the news |
|
Blogs on Chronic lymphocytic leukemia diagnostic study of choice |
|
Directions to Hospitals Treating Chronic lymphocytic leukemia |
|
Risk calculators and risk factors for Chronic lymphocytic leukemia diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
The diagnostic study of choice in chronic lymphocytic leukemia is according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines which involves complete blood count (CBC) with differential and peripheral smear flow cytometry.
Diagnostic study of choice
The diagnostic study of choice in chronic lymphocytic leukemia is peripheral blood flow cytometry. If peripheral blood flow cytometry shows greater than 5000 clonal B cell per microliter, the diagnosis is confirmed. Ancillary tests include bone marrow biopsy and peripheral blood cytogenetics or FISH studies.
Chronic lymphocytic leukemia is diagnosed according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines:[1][2]
- Complete blood count (CBC) with differential: Absolute lymphocytosis ≥5000 B-lymphocytes/µL X ≥ 3 months
- Flow cytometry: B lymphocytes clonality (Immunoglobulin light chain restriction)
Presence of clonal B-lymphocutosis <5000/µL without cytpenia, hepatosplenomegaly, lymphadenopathy or other disease-related symptoms can be defined as monoclonal B lymphocytosis (MBL). MBL will progress to CLL at a rate of 1% to 2% per year.[3]
References
- ↑ Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ (June 2018). "iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL". Blood. 131 (25): 2745–2760. doi:10.1182/blood-2017-09-806398. PMID 29540348.
- ↑ Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ (November 1988). "Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group". Am. J. Hematol. 29 (3): 152–63. PMID 3189311.
- ↑ Rawstron AC, Bennett FL, O'Connor SJ, Kwok M, Fenton JA, Plummer M, de Tute R, Owen RG, Richards SJ, Jack AS, Hillmen P (August 2008). "Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia". N. Engl. J. Med. 359 (6): 575–83. doi:10.1056/NEJMoa075290. PMID 18687638.